Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Pulse Biosciences (PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team is scheduled to deliver their presentation on Wednesday, January 15, 2025, at 3:45 PM Pacific Time.
Investors and interested parties can access both the live and recorded versions of the presentation through the company's investor relations website, specifically on the 'Events Calendar and Presentations' page at investors.pulsebiosciences.com.
Pulse Biosciences (PLSE), un pioniere nella tecnologia Nanosecond Pulsed Field Ablation™ (nano-PFA), ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference a San Francisco. Il team di gestione dell'azienda è programmato per presentare il loro intervento mercoledì 15 gennaio 2025, alle 15:45 ora del Pacifico.
Gli investitori e le parti interessate possono accedere sia alla versione dal vivo che a quella registrata della presentazione tramite il sito web delle relazioni con gli investitori dell'azienda, specificamente nella pagina 'Calendario Eventi e Presentazioni' su investors.pulsebiosciences.com.
Pulse Biosciences (PLSE), un pionero en la tecnología Nanosecond Pulsed Field Ablation™ (nano-PFA), ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan en San Francisco. El equipo de gestión de la empresa está programado para realizar su presentación el miércoles 15 de enero de 2025, a las 3:45 PM Hora del Pacífico.
Los inversores y partes interesadas pueden acceder tanto a la versión en vivo como a la grabada de la presentación a través del sitio web de relaciones con inversores de la empresa, específicamente en la página 'Calendario de Eventos y Presentaciones' en investors.pulsebiosciences.com.
Pulse Biosciences (PLSE)는 Nanosecond Pulsed Field Ablation™ (nano-PFA) 기술의 선구자로서 샌프란시스코에서 열리는 제43회 연례 J.P. Morgan 의료 회의에 참여한다고 발표했습니다. 회사의 경영진 팀은 2025년 1월 15일 수요일, 태평양 시간 기준으로 오후 3시 45분에 발표를 진행할 예정입니다.
투자자 및 관심 있는 분들은 회사의 투자자 관계 웹사이트를 통해 발표의 실시간 및 녹화된 버전에 접근할 수 있으며, '이벤트 일정 및 발표' 페이지인 investors.pulsebiosciences.com에서 확인하실 수 있습니다.
Pulse Biosciences (PLSE), un pionnier dans la technologie Nanosecond Pulsed Field Ablation™ (nano-PFA), a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare à San Francisco. L'équipe de direction de l'entreprise doit présenter sa présentation le mercredi 15 janvier 2025, à 15h45 heure du Pacifique.
Les investisseurs et les parties intéressées peuvent accéder aux versions en direct et enregistrées de la présentation via le site web des relations investisseurs de l'entreprise, plus précisément sur la page 'Calendrier des événements et présentations' à investors.pulsebiosciences.com.
Pulse Biosciences (PLSE), ein Pionier in der Technologie Nanosecond Pulsed Field Ablation™ (nano-PFA), hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco angekündigt. Das Management-Team des Unternehmens wird voraussichtlich am Mittwoch, den 15. Januar 2025, um 15:45 Uhr Pazifischer Zeit seine Präsentation halten.
Investoren und Interessierte können sowohl auf die Live- als auch auf die aufgezeichnete Version der Präsentation über die Website für Investorenbeziehungen des Unternehmens zugreifen, insbesondere auf der Seite 'Veranstaltungskalender und Präsentationen' unter investors.pulsebiosciences.com.
- None.
- None.
Pulse Biosciences’ Management is scheduled to present on Wednesday, January 15, 2025, at 3:45 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250103001491/en/
Investors:
Pulse Biosciences, Inc.
Darrin Uecker, CTO or Kevin Danahy, CCOIR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
When is Pulse Biosciences (PLSE) presenting at the JP Morgan Healthcare Conference 2025?
How can investors watch Pulse Biosciences' (PLSE) JP Morgan Healthcare Conference presentation?
What is the main technology focus of Pulse Biosciences (PLSE)?
Where is the 2025 JP Morgan Healthcare Conference featuring PLSE being held?
